Advances and challenges in malaria vaccine development
Advances and challenges in malaria vaccine development
复制标题
DOI：
10.1172/jci44423
复制
发表时间：
2010-12-01
影响因子：
15.9
通讯作者：
Miller, Louis H.
中科院分区：
文献类型：
--
作者：
Crompton, Peter D.;Pierce, Susan K.;Miller, Louis H.
由恶性疟原虫引起的疟疾仍然是一个主要的公共卫生威胁，特别是在非洲的儿童和孕妇中。有效的疟疾疫苗将是减少疾病负担的宝贵工具，并有助于在世界某些区域消除疟疾。目前的候选疟疾疫苗针对的是寄生虫生命周期的人类和蚊子阶段，但迄今为止，研究的用于潜在疫苗开发的蛋白质相对较少。最先进的候选疫苗RTS，S在II期临床试验中提供了对疟疾的部分保护，目前正在非洲的III期试验中进行评估。需要确定新的疫苗靶点，以提高开发高效疟疾疫苗的机会。更好地了解疟疾自然获得性免疫的机制可能导致对疫苗开发的见解。
Malaria caused by Plasmodium falciparum remains a major public health threat, especially among children and pregnant women in Africa. An effective malaria vaccine would be a valuable tool to reduce the disease burden and could contribute to elimination of malaria in some regions of the world. Current malaria vaccine candidates are directed against human and mosquito stages of the parasite life cycle, but thus far, relatively few proteins have been studied for potential vaccine development. The most advanced vaccine candidate, RTS,S, conferred partial protection against malaria in phase II clinical trials and is currently being evaluated in a phase III trial in Africa. New vaccine targets need to be identified to improve the chances of developing a highly effective malaria vaccine. A better understanding of the mechanisms of naturally acquired immunity to malaria may lead to insights for vaccine development.